Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Hold” from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has earned a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.33.

A number of research analysts have recently issued reports on ESPR shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a report on Wednesday, April 10th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Finally, Bank of America lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR opened at $1.95 on Friday. The firm has a market capitalization of $369.33 million, a PE ratio of -0.92 and a beta of 0.84. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.40. The stock’s 50-day simple moving average is $2.48 and its 200-day simple moving average is $1.95.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the previous year, the firm posted ($0.76) EPS. On average, sell-side analysts forecast that Esperion Therapeutics will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently modified their holdings of ESPR. Chicago Partners Investment Group LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at approximately $29,000. Private Portfolio Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter worth $30,000. Simplicity Solutions LLC purchased a new stake in Esperion Therapeutics during the third quarter worth $30,000. Sei Investments Co. boosted its position in Esperion Therapeutics by 78.7% during the first quarter. Sei Investments Co. now owns 20,979 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 9,242 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Esperion Therapeutics by 199.7% during the first quarter. Tower Research Capital LLC TRC now owns 20,907 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 13,932 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.